Researchers studying 278 patients with in-stent restenosis found that B. Braun‘s SeQuent Please paclitaxel-eluting balloon was non-inferior to Abbott‘s (NYSE:ABT) Xience drug-eluting stent when it comes to six-month minimal lumen diameter.
The study’s results were touted this week at the annual Transcatheter Cardiovascular Therapeutics conference in Denver, Colorado.
Get the full story at our sister site, Drug Delivery Business News.
The post TCT 2017: Drug-eluting balloon achieves non-inferiority with drug-eluting stent appeared first on MassDevice.